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a b s t r a c t
Presence of perivascular neuroblastoma cells with high expression of hypoxia inducible factor (HIF)-2a
correlates with distant metastasis and aggressive disease. Regulation of HIFs are traditionally considered
to occur post-translationally, but we have recently shown that HIF-2a is unconventionally regulated also
at the transcriptional level in neuroblastoma cells. Regulatory factors binding directly to EPAS1 (encoding
HIF-2a) to promote transcription are yet to be deﬁned. Here, we employ the novel CRISPR/Cas9-based
engineered DNA-binding molecule-mediated chromatin immunoprecipitation (enChIP) e mass spec-
trometry (MS) methodology to, in an unbiased fashion, identify proteins that associate with the EPAS1
promoter under normoxic and hypoxic conditions. Our enChIP analysis resulted in 27 proteins binding to
the EPAS1 promoter in neuroblastoma cells. In agreement with a general hypoxia-driven downregulation
of gene transcription, the majority (24 out of 27) of proteins dissociate from the promoter at hypoxia.
Among themwere several nucleosome-associated proteins suggesting a general opening of chromatin as
one explanation to induced EPAS1 transcription at hypoxia. Of particular interest from the list of released
factors at hypoxia was the highly divergent homeobox (HDX) transcription factor, that we show inversely
correlates with HIF-2a in neuroblastoma cells. We propose a putative model where HDX negatively
regulates EPAS1 expression through a release-of-inhibition mechanism.
© 2018 Elsevier Inc. All rights reserved.
1. Introduction
Neuroblastoma cells at low oxygen (i.e. hypoxia) de-
differentiate and acquire stem cell-like features [1]. Hypoxia-
inducible factors (HIF)-1 and HIF-2 are key regulators of the
cellular response to hypoxia. Expression of HIF-a proteins correlate
with unfavorable disease in numerous cancer forms, and in neu-
roblastoma expression of HIF-2a protein correlates to poor patient
outcome and disseminated disease while HIF-1a expression levels
lack prognostic value [2,3]. Perivascular neuroblastoma cells
expressing unexpectedly high levels of HIF-2a are immature and
neural crest-like [4], and similar observations have been reported in
glioma [5]. Interestingly, EPAS1 (encoding HIF-2a) is expressed
during discrete periods of early developmental stages of human
sympathetic nervous system (SNS) [6,7]. HIF-2a accumulation is
promoted at the mRNA level [7e9] and given the expression pat-
terns of HIF-2a during normal SNS development and the positive
association to neuroblastoma tumor progression, understanding of
molecular events regulating HIF-2a expression in neuroblastoma
may open up for novel treatment strategies.
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The CRISPR/Cas9 system has turned out to be an extremely
efﬁcient technique to edit the genomic architecture [10]. Recently,
the CRISPR/Cas9-based engineered DNA-binding molecule-medi-
ated chromatin immunoprecipitation (enChIP) - mass spectrom-
etry (MS) approach was developed to combine and take advantage
of the dCas9 and SILAC-MS technologies [11,12]. With enChIP-MS,
quantitative changes in proteins that bind to gRNA-targeted DNA
regions can be identiﬁed in an unbiased fashion.
Since accumulation of HIF-2a protein correlates with EPAS1
mRNA levels, and the increase in mRNA is not the result of mRNA
stabilization [9], we have used the enChIP-MS approach to unravel
an unbiased protein signature associated with the EPAS1 promoter
after a normoxic to hypoxic shift. We conﬁrm that individual pro-
teins binding to EPAS1 can be successfully isolated and identiﬁed
using enChIP-MS. Among the proteins less abundantly bound to the
EPAS1 promoter at hypoxia were several groups of histones as well
as nucleophosmin (NPM1), indicating a general opening of the
chromatin structure. This partly explains increased EPAS1 tran-
scription at hypoxic conditions. As proof-of-principle for applica-
tion of enChIP-MS, we show that the HDX transcription factor e
with two putative binding sites in the regulatory region of EPAS1 e
is less expressed in neuroblastoma cells cultured at hypoxia. With
support from mouse and human tumor gene expression data, we
propose a model where HDX might be involved in a release-of-
inhibition mechanism of EPAS1 expression.
2. Materials and methods
2.1. Cell culture and transfection
Human neuroblastoma cell lines SK-N-BE(2)c and IMR-32
(ATCC) were cultured as described [7]. Cell lines were regularly
screened for mycoplasma. Culture conditions and handling of
neuroblastoma cell lines and tissues analyzed by global expression
approach has been described [13]. Neuroblastoma patient-derived
xenograft (PDX) cells were isolated and cultured as previously
described [14]. HEK293T cells (ATCC) were cultured in DMEM
medium supplemented with 10% FBS and antibiotics. Hypoxia was
generated in a Whitley H35 Hypoxystation (Don Whitley Scienti-
ﬁc). Transfection was performed using siRNAs (20 nM) targeting
HDX (s44196/Exon9/10; s44198/Exon3/4; Customized/Exon1;
Ambion) or non-targeting control siRNA with RNAiMAX (Thermo-
Fisher Scientiﬁc).
2.2. Tissues
Sympathetic ganglia containing hyperplastic neuroblast foci
were harvested from Th-Mycnþ/þmice [15] at days 7 (n¼ 4) and 14
(n¼ 4). Advanced neuroblastic tumors (n¼ 4) were obtained after 6
weeks. As control, sympathetic ganglia were obtained from Th-
Mycn#/# mice at corresponding developmental stages. Total RNA
was proﬁled on Agilent SurePrint G3 Gene Expression Microarrays
according to the manufacturer's protocols. Data were summarized
and normalized with the vsn method in the R statistical program-
ming language using the limma package.
2.3. Promoter evaluation
The promoter region of EPAS1 (±3 kbp) was examined for suit-
able guide RNA (gRNA) target regions by BLAST search (RefSeq
NM_001430). Sequence regions with required endonuclease motif
were evaluated for overlap with publically available ChIP-Seq
datasets; ENCODE database [16], interspersed repeats and low
complexity DNA sequence; RepeatMasker, http://www.
repeatmasker.org, and conservation; GERP [17]. Chromatin States
were obtained from the UCSC genome browser.
2.4. enChIP preparation
To construct gRNA_hEPAS1#2 (gRNA target sequence: aaggg-
cacggcgccggtacgagg), gRNA cloning vector (Addgene #41824, kind
gift from George Church) was used for Gibson assembly as previ-
ously described [18]. To construct gRNA_hEPAS1#2/pSIR, the
gBlock excised from gRNA_hEPAS1#2 was inserted into pSIR self-
inactivating retrovirus vector (Clontech). To examine target speci-
ﬁcity of gRNA_hEPAS1#2, 3xFLAG-dCas9/pCMV-7.1 (Addgene
#47948) [11] and gRNA_hEPAS1#2 were transfected into HEK293T
cells. Cells were ﬁxed with 1% formaldehyde at 37 $C for 5min. The
chromatin fraction was extracted, fragmented by sonication, and
used for enChIP as previously described [11,12,19]. Puriﬁed DNAwas
used for real-time PCR as previously described [11]. Primers are
listed in Supplementary Table S1. The 3xFLAG-dCas9/pMXs-puro
(Addgene #51240) and gRNA_hEPAS1#2/pSIR plasmids were
generated and sequentially transduced into neuroblastoma SK-N-
BE(2)c cells. Cells were incubated with culture medium diluted
viral supernatant in presence of 5 mg/ml polybrene (Sigma) for 24 h.
Puromycin (0.7 mg/ml) selection started after 72 h for 3xFLAG-
dCas9/pMXs-puro. Similarly, G418 (0.8mg/ml) selectionwas added
72 h post transduction of gRNA_hEPAS1#2.
2.5. enChIP-MS
enChIP-MS was performed as described previously [11,12,19]. In
short, 3xFLAG-dCas9 and gRNA_hEPAS1#2 expressing SK-N-BE(2)c
neuroblastoma cells were grown in MEM and dialyzed FBS (Ther-
moFisher Scientiﬁc) with Lysine-2HCL and L-Arginine-HCL (Ther-
moFischer Scientiﬁc) (Light SILAC Medium) or 13C6 15N4 L-
Arginine-HCL and 13C6 L-Lysine-HCL (ThermoFisher Scientiﬁc)
(Heavy SILACMedium). 5% 107 cells grown in Heavy SILACMedium
were subjected to hypoxia and mixed with 5% 107 cells grown in
Light SILAC Medium at normoxia for 72 h. Cells were ﬁxed in 1%
formaldehyde and neutralized with glycine solution. Chromatin
was isolated and fragmented by sonication to obtain average length
of 1.5 kb fragments and used for enChIP as previously described
[12]. MS was performed on enChIP samples using a nanoLC-MS/MS
system at DNA-chip Development Center for Infectious Diseases
(RIMD, Osaka University) as described in Ref. [12]. The MS analysis
was performed in duplicate.
2.6. Quantitative real-time PCR
Total RNA was extracted using the automated extraction robot
Arrow (DiaSorin) after being prepared according to the manufac-
turer's recommendation. cDNA synthesis and quantitative PCR
analysis was performed as described in Ref. [8]. Primers are listed in
Supplementary Table S1.
2.7. Western blot
Western blot analyses were performed as previously described
[9]. SK-N-BE(2)c cell cytoplasm and nuclei were fractionated using
NE-PER (ThermoFisher Scientiﬁc). Antibodies used: anti-FLAG
(#F3165, Sigma), anti-SDHA (#Ab14715, Abcam), anti-HIF-2a
(Ab199, Abcam), anti-Actin (#691001, MP Biomedical), anti-HDX
(#SAB1400801, Sigma), anti-Lamin B1 (ab16048, Abcam), anti-
mouse (#62e6520, Invitrogen) and anti-rabbit (#65e6120,
Invitrogen).
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2.8. Gene expression and RNAseq analyses
Normalized data from the Cancer Cell Line Encyclopedia (CCLE)
expression dataset [13] (GSE36133) and an RNAseq dataset con-
sisting of 498 tumors (GSE62564) were acquired from R2: micro-
array analysis and visualization platform (http://r2.amc.nl). Only
tumors with a known MYCN-status were included in the analyses
(n¼ 493). Data was analyzed using R statistical language (version
3.1.1).
2.9. Statistical analyses
Two-sided Student's unpaired t-test was used for statistical
analyses, *p < 0.05, **p < 0.01, ***p < 0.001. Pearson's product
moment correlation coefﬁcient and accompanying p-values were
used for correlation analyses.
3. Results
3.1. EPAS1 gRNA target sequence displays sufﬁcient enChIP yield
In search for suitable target sequences close enough to the re-
ported transcription start site (TSS), yet in a non-occupied region to
retain molecular interactions, promoter evaluation of EPAS1 was
performed (Fig. 1A). Within a 6 kb DNA sequence surrounding TSS
(±3 kb) of the EPAS1 promoter a suitable gRNA target sequence was
found 400 bp 50 to the TSS (Fig. 1A). Isolation efﬁciency of endog-
enous EPAS1 promoter locus was veriﬁed in a transient expression
systemwith HEK293T cells. enChIP-PCR revealed that 5.1% of input
genomic DNA was immunoprecipitated for the target EPAS1 pro-
moter locus (Fig. 1B). Selectivity of our experimental approach was
veriﬁed by analyzing enChIP yields of more distal sites and the
unrelated SOX2 locus. The percentage of input signal gradually
decreased with increasing distance from the target site, and the
yield for the SOX2 locus was as low as the yield obtained for the
gRNA cloning vector (Fig. 1B).
Expression of dCas9 and gRNA was veriﬁed in cells transduced
with 3xFLAG-dCas9 and gRNA_hEPAS1#2 (Fig. 1C). We also
controlled the effects of introducing 3xFLAG-dCas9 (in ﬁgures
referred to as #4) and gRNA_hEPAS1#2 on the expression of EPAS1
after each step (Fig. 1DeF). Further, wild type SK-N-BE(2)c cells
(WT) and cells expressing 3xFLAG-dCas9 and gRNA_hEPAS1#2 (in
ﬁgures referred to as #4 þ 5) were cultured at normoxia and
hypoxia in SILAC medium to verify that this did not affect EPAS1
induction (Fig. 1DeF).
3.2. Rictor and N-Myc networks revealed as top regulators
enChIP-MS analysis was carried out using SK-N-BE(2)c cells
stably expressing 3xFLAG-dCas9 and gRNA_hEPAS1#2, in search for
regulatory proteins with altered binding to the EPAS1 promoter
region in response to hypoxia. Cells stably expressing 3xFLAG-
dCas9 and gRNA_hEPAS1#2 were cultured at normoxia in Light
SILAC medium or at hypoxia in Heavy SILAC medium. Cross-linked
and isolated chromatin was sonicated to achieve DNA fragments in
the size range of 0.25e3.0 kb, with an average length of 1.5 kb
(Supplementary Fig. S1A). The fragments were subjected to anti-
FLAG-enChIP, and subsequently SILAC-MS analysis. As a result, for
every detected protein, a Heavy/Light (H/L) ratio was obtained [12].
Translating these data to our biological setting, all H/L ratios >1
could suggest that these proteins aremore abundantly bound to the
EPAS1 promoter at hypoxia and proteins with H/L ratios <1 less
abundant.
A total of 220 proteins were detected from the enChIP-MS
analysis (Supplementary Table S2). When subjected to QIAGEN's
Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, www.
qiagen.com/ingenuity) N-Myc and Rictor were disclosed among
the top regulator effect networks (Table 1). Rictor is a critical
component of mTORC2, recently demonstrated to be involved in
EPAS1 transcription [8]. Association of N-Myc to the identiﬁed
proteins is also of potential interest, given the role of MYCN in
aggressive neuroblastomas and that SK-N-BE(2)c cells harbor a
MYCN ampliﬁcation.
Filtering out proteins without a deﬁned H/L ratio left 165 pro-
teins robustly inﬂuenced by hypoxia. Of these proteins, 42 were
categorized based on their involvement in transcriptional regula-
tion and 33 proteins were identiﬁed as sequence-speciﬁc DNA
binding transcription factors according to their GO annotations
(Table 1). As an alternative approach to narrow down the 165-
protein hits, we ﬁltered for those proteins that showed a smaller
mean H/L variability than 20% between the two MS measurements,
leaving 82 proteins (Table 1).
3.3. Chromatin-modifying proteins are released from the EPAS1
promoter at hypoxia
The majority of identiﬁed proteins were downregulated by
hypoxia, including nucleosome-associated proteins such as his-
tones H2ah, H2bk, H3a, H4a and the histone chaperone nucleo-
phosmin (NPM1) (Tables 1 and 2). Since these chromatin-
modifying proteins were less bound to the EPAS1 promoter at
hypoxia, we speculate that opening of the chromatin surrounding
EPAS1 is one contributing mechanism to hypoxia-induced EPAS1
expression. Furthermore, loosening of the chromatin is associated
with an immature phenotype, which is in accordance with the de-
differentiating effect of hypoxia on neuroblastoma cells [1].
3.4. enChIP-MS-identiﬁed HDX negatively correlates with EPAS1 in
neuroblastoma
To focus on proteins with highest relevance to our setting, we
cross-referenced our enChIP-MS data to previously reported
enChIP-MS data [11,12] in order to exclude putative overlaps. This
approach left us with 27 EPAS1 speciﬁc promoter-associated pro-
teins in neuroblastoma (Table 2), and 24 of these proteins were
dissociated as a result of hypoxia. One potentially interesting pro-
tein strongly dissociated from the EPAS1 promoter upon hypoxia is
the highly divergent homeobox (HDX) transcription factor.
Intriguingly, neuroblastoma cells and cells derived from the auto-
nomic ganglia in general display the highest expression of HDX of
all cell types listed in the Cancer Cell Line Encyclopedia [13]
(Fig. 2AeB). Of note, these cell types also display the highest levels
of MYCN expression (Supplementary Figs. S1BeC). In a panel of 17
analyzed human neuroblastoma cell lines, EPAS1 expression was
lowest in cell lines with highest expression of HDX (Fig. 2C).
Importantly, neuroblastoma IMR-32 cells, which we previously
have shown to virtually lack expression of EPAS1 [7], display among
the highest HDX expression levels (Fig. 2C). In a large cohort of
primary neuroblastoma samples, an overall modest negative cor-
relation was observed between EPAS1 and HDX mRNA expression
(Fig. 2D). This negative correlation could be attributed to inversed
levels of HDX and EPAS1 when divided by MYCN-status (Fig. 2E).
Modest or no correlation between HDX and EPAS1 was detected
when MYCN-ampliﬁed or non-ampliﬁed tumors were examined
separately (Supplementary Figs. 1DeE). Together these data may
suggest a causative or synergistic role betweenMYCN andHDXwith
regards to the regulation of EPAS1 expression. In line with obser-
vations in primary tumors, Hdx levels increased over time in the
hyperplastic paravertebral ganglia of developing Mycn-driven tu-
mors from the Th-Mycnmouse model of neuroblastoma [15], while
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Epas1 levels were diminished as compared to the ganglionic
expression in the wild type mice (Fig. 2FeG).
3.5. HDX and HIF-2a expression correlates negatively in
neuroblastoma cells
HIF-2a expression increases gradually over time at hypoxia in
Fig. 1. Veriﬁcation of enChIP procedure. (A) Promoter evaluation of a 6 kb region surrounding the EPAS1 transcription start site (TSS). Publically available data were analyzed based
on cumulative ChIP-seq overlap, interspersed repeats and low complexity DNA sequences, GERP conservation among species and chromatin status in a battery of cell lines. gRNA
target sequence 400 bp 50to TSS is enlarged. (B) Yield of enChIP analysis for the target site, distal sites (#0.3 kb and #0.1 kb) and control SOX2 locus. 3xFLAG-dCas9 and gRNA cloning
vector lacking functional gRNA (gRNA-EV) served as control. (C)Western blot analysis of SK-N-BE(2)c wild type (WT) and 3xFLAG-dCas9 (#4) expressing cells with anti-FLAG. SDHA
served as loading control. (D) 3xFLAG-dCas9 (#4) expressing cells analyzed for EPAS1mRNA expression by qRT-PCR. SEM from two independent experiments presented. (E)WTand
3xFLAG-dCas9 (#4) and gRNA_hEPAS#2 expressing cells analyzed for gRNA_hEPAS1#2 speciﬁc scaffold and EPAS1 mRNA expression. SEM from ﬁve independent experiments
presented. (F) 3xFLAG-dCas9 and gRNA_hEPAS#2 (#4 þ 5) expressing cells cultured in Light- or Heavy medium (SILAC) analyzed for gRNA_hEPAS1#2 speciﬁc scaffold and EPAS1
mRNA expression. Error bars represent SD from one experiment. (DeE) Cells were cultured at 21% or 1% O2 for 72 h. Statistical signiﬁcance was calculated using Student's t-test: *,
P < 0.05; **, P < 0.01; ***, P < 0.001. No asterisk indicates no signiﬁcance.
Table 1
Predicted upstream regulators identiﬁed through QIAGEN's Ingenuity® Pathway Analysis (IPA®) (top panel). Summary of the identiﬁed EPAS1-associated proteins pulled down
with gRNA_hEPAS1#2; all hits with larger mean Heavy/Light variability than 20% from two MS measurements were ﬁltered, leaving 82 proteins (middle panel). An overall
down-regulation of nucleosome forming proteins including histones and the histone chaperone NPM1 at hypoxia was observed (lower panel). The complete list of proteins
identiﬁed by enChIP-MS with gRNA_hEPAS1#2 is presented in Supplementary Table S2.
Effector Description Involvment
MYCN v-myc avian myelocytomatosis viral oncogene Proliferation and cell movement
NFE2L2 neuroblastoma derived homolog nuclear factor, erythroid 2-like 2
RICTOR Rapamycin independent companion of mTOR, complex 2
MYC v-myc avian myelocytomatosis viral oncogene homolog
Identiﬁed hits Inﬂuenced hits Gene expression-
Inﬂuenced hits
Sequence-speciﬁc DNA binding TF activity Inﬂuenced ﬁltered hits
220 165 42 33 82
Nucleosome-associated proteins Mean H/L Ratio
HIST1H2AH histone cluster 1, H2ah 0.373
HIST1H4A histone cluster 1, H4a 0.366
HIST1H2BK histone cluster 1, H2bk 0.297
HIST1H3A histone cluster 1, H3a 0.205
NPM1 nucleophosmin (nucleolar phosphoprotein B23, numatrin) 0.266
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SK-N-BE(2)c and PDX-derived LU-NB-3 neuroblastoma cells [14],
whereas expression of HDX is not affected at the mRNA level in
these cells (Fig. 3AeB). Expression of HDX protein decreased at
hypoxia when analyzing whole cell lysates, and this decrease was
even more pronounced in the nuclear fraction (Fig. 3B), i.e. at
conditions when EPAS1 mRNA is induced and HIF-2a protein sta-
bilized (Fig. 3B). IMR-32 cells express high levels of HDX but
virtually lack expression of EPAS1 (Fig. 2C). Although knockdown
efﬁciency of three different siRNA oligonucleotides targeting three
different HDX exons in these cells was weak, all three siRNAs
resulted in a small but signiﬁcant increase in EPAS1 expression
(Fig. 3C).
To identify putative HDX binding sites in the active chromatin
regions of EPAS1, we subjected a 3000 bp region of the EPAS1
promoter (500 bp 50and 2500 bp 30 of the reported TSS) to the
transcription factor motif-analysis software, SMART [20]. Two po-
tential binding motifs for HDX were found on the reverse strand,
1725 bp and 2367 bp 30to the TSS respectively, a region between
exon 1 and exon 2 where most activity indeed seems to take place
(Fig. 3D).
4. Discussion
The genetic landscape of primary neuroblastomas has been
characterized in detail, showing low mutational burden and few
recurrent mutations [21]. Despite these efforts, understanding of
transcriptional rewiring in malignant neuroblasts is still limited. To
unravel interactions inducing EPAS1 expression in neuroblastoma,
we employed the novel CRISPR/Cas9-based enChIP-MS technology
in a retroviral expression setting [12]. We successfully targeted the
EPAS1 promoter which allowed us to identify a set of proteins
speciﬁcally bound to the promoter region at normoxia and hypoxia.
Many of the identiﬁed proteins such as histones, acetyltransferases
and RNA polymerase associated proteins were partly expected and
indicated a more open chromatin state. The majority of enChIP-
retrieved proteins showed decreased binding to the EPAS1
promoter at hypoxia. This indicates that the increase in EPAS1
transcription is primarily the result of dissociated promoter-
associated factors, in line with our previous data where far more
negative than positive regulators of EPAS1 transcription were
identiﬁed using an RNAi-mediated knockdown array [9].
HDX was a top hit from our enChIP-MS analysis, and we show
that the EPAS1 ﬁrst intron harbors two putative HDX binding sites.
The overall function of HDX is poorly investigated, but we
demonstrate that it is highly expressed in cells derived from
autonomic ganglia and neuroblastoma in particular. Of note, these
tumors and tissues also displayed the highest expression of MYCN.
In line with the low SILAC-MS H/L ratio for HDX, a trend towards an
inverse correlation between EPAS1 andHDX expression in normoxic
neuroblastoma cell lines was observed, with the MYCN non-
ampliﬁed cell lines displaying lower levels of HDX and higher
levels of EPAS1. This negative correlation was also observed when
examining a cohort of neuroblastoma tumors. Once again, the
correlation appeared dependent on higher levels of HDX and lower
levels of EPAS1 in MYCN-ampliﬁed tumors. Interestingly, N-Myc
was predicted as one of the main upstream regulators of proteins
bound to the EPAS1 promoter, suggesting a potential modulatory
role of MYCN in the relationship between EPAS1-promoter bound
proteins (such as HDX) and EPAS1 expression. In further support of
this, Mycn-driven tumor development in Th-Mycn mice displayed
increased Hdx and decreased Epas1 expression over time. All
together, these data may point to an N-Myc-dependency of HDX in
regulating EPAS1 expression.
Overall, our results suggest a release-of-inhibition mechanism
for HDX-dependent EPAS1 transcription as demonstrated by
enChIP-MS data. Using the EPAS1 gene as proof of concept, we show
here that relevant promoter-binding proteins of genes-of-interest
can be retrieved. Since these isolated proteins are in their func-
tional conﬁgurations, further analyses may disclose post-
translational modiﬁcations with novel treatment targets as a
possibility.
Table 2
Summary of the 27 most signiﬁcant hits. Mean H/L Ratio, peptide count and variability for both measurements was calculated; variability >20% was excluded from the list.
Gene ID Description Location Mean H/L Ratio Mean Peptide Count Mean H/L Variability (%)
IVNS1ABP Inﬂuenza virus NS1A binding protein 1q 2.116 5 14.8
RAB11B RAB11B, member RAS oncogene family 19p 1.360 9 12.4
STOML2 Stomatin (EPB72)-like 2 9p 1.190 4 11.0
PAFAH1B2 platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 11q 0.967 4 7.2
HSPD1 heat shock 60kDa protein 1 (chaperonin) 2q 0.848 2 4.5
HSPA9 heat shock 70kDa protein 9 (mortalin) 5q 0.668 4 13.6
PITPNB phosphatidylinositol transfer protein, beta 22q 0.575 5 14.3
ACTN1 actinin, alpha 1 14q 0.551 3 15.7
HSPB1 heat shock factor binding protein 1 16qc 0.556 8 18.4
PTS 6-pyruvoyltetrahydropterin synthase 11q 0.562 8 15.6
SNRPB small nuclear ribonucleoprotein polypeptides B and B1 20p 0.529 4 16.9
NT5C2 5’-nucleotidase, cytosolic II 10q 0.479 42 12.9
U2AF1L4 U2 small nuclear RNA auxiliary factor 1-like 4 19qc 0.444 10 14.5
MYH10 myosin, heavy polypeptide 10, non-muscle 17p 0.442 81 18.7
HDX highly divergent homeobox Xq 0.397 23 18.6
PSMA4 proteasome subunit alpha 4 15q 0.407 22 18.9
HIST1H2AH histone cluster 1, H2ah 6p 0.373 16 12.7
HIST4H4 histone cluster 4, H4 12p 0.366 21 11.8
HIST1H2BK histone cluster 1, H2bk 6p 0.297 10 19.1
LMNB1 lamin B1 5q 0.270 2 19.2
CCAR1 cell division cycle and apoptosis regulator 1 10q 0.244 4 6.4
STK38 serine/threonine kinase 38 6p 0.225 7 6.7
ERH enhancer of rudimentary homolog (Drosophila) 14q 0.207 11 8.6
DLG1 discs, large homolog 1 3q 0.189 4 13.0
SPIN1 spindlin 1 9q 0.145 17 19.8
EIF4B eukaryotic translation initiation factor 4B 12q 0.122 5 17.9
NDFIP1 Nedd4 family interacting protein 1 5q 0.020 4 3.3
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Fig. 2. HDX and EPAS1 expression correlates negatively. HDX expression across a series of tumor cell lines (Cancer Cell Line Encyclopedia; CCLE) separated according to tumor type
(A) and tumor tissue of origin (B). (C) EPAS1 and HDX expression across cell lines present in the CCLE. (D) EPAS1 vs. HDX expression in 493 neuroblastomas. Pearson product-moment
correlation coefﬁcient (R) and corresponding p-values (p) are displayed. (E) Boxplots of HDX (top) and EPAS1 (bottom) expression in the 493 neuroblastoma tumors divided ac-
cording to MYCN-status. (F) and (G) Expression of HDX and EPAS1 in sympathetic ganglia containing hyperplastic lesions, and advanced tumors from TH-MYCNþ/þ mice at,
respectively, 1 and 2 weeks and 6 weeks of age (orange), and in normal sympathetic ganglia from wild-type mice at 1, 2 and 6 weeks of age (purple). Data are presented as
mean ± standard deviation of four samples. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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